There **is an ongoing class action-style multidistrict litigation (MDL) against Suboxone** related to dental injuries, particularly severe tooth decay and other oral health problems. This litigation involves hundreds of plaintiffs across the United States who allege that Suboxone, a medication used to treat opioid addiction, caused significant dental damage such as tooth decay, enamel erosion, tooth loss, and gum disease. The core claim is that the manufacturer, Indivior, knew or should have known about these risks but failed to adequately warn patients and healthcare providers for many years.
Suboxone contains buprenorphine and naloxone and is administered as a sublingual film dissolved in the mouth. This method of delivery has been linked to dental problems because the medication stays in contact with the teeth and gums for extended periods. Many users have reported dry mouth, which reduces saliva production—a natural protector against tooth decay—and this contributes to the worsening of dental health. The dental issues reported include cavities, cracked or fractured teeth, infections, and even the need for crowns or tooth extractions.
The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication in 2022 warning about dental problems associated with buprenorphine medications dissolved in the mouth, including Suboxone. This warning highlighted that dental injuries could occur even in patients without prior dental issues. However, plaintiffs argue that this warning came too late and that the drug maker failed to inform users and medical professionals earlier despite evidence of these risks.
The lawsuits have been consolidated into an MDL in the Northern District of Ohio, which streamlines the handling of these cases. As of late 2024 and into 2025, the MDL includes hundreds of active cases, with ongoing court orders requiring plaintiffs to submit detailed information about their Suboxone use and dental injuries. This consolidation allows for coordinated discovery and pretrial proceedings, which is typical in large-scale product liability cases.
Plaintiffs in these lawsuits seek compensation for the extensive dental procedures they have had to undergo, emotional distress, and other damages resulting from the alleged failure to warn. The lawsuits also raise broader questions about corporate responsibility and whether the manufacturer prioritized profits over patient safety by withholding critical information about the drug’s side effects.
If someone has taken Suboxone and experienced severe dental problems afterward, they may be eligible to join the litigation or file a claim. Law firms specializing in product liability are actively investigating these cases and offering free consultations to potential claimants. The litigation is ongoing, and while no final settlements or verdicts have been widely publicized yet, the volume of cases and court activity indicates a significant legal response to these dental injury claims.
In summary, there is a substantial and active legal movement against Suboxone’s manufacturer regarding dental injuries, structured as a multidistrict litigation that functions similarly to a class action by consolidating many individual claims into one coordinated process. This reflects growing recognition of the serious dental risks associated with Suboxone use and the alleged failure of the manufacturer to provide adequate warnings.
